Stem cell therapy for infants with biliary atresia and cirrhosis
Part of Digestive system, Genetic & congenital clinical trials.
This study is testing whether stem cells can help infants with liver cirrhosis from biliary atresia (a blocked bile duct condition) who have already had Kasai surgery. It aims to see if stem cell therapy can improve liver function and reduce complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your baby has been diagnosed with liver scarring (cirrhosis) caused by biliary atresia, even after having Kasai surgery.
- Your baby is at least 2 months old and shows signs of cirrhosis, such as an enlarged liver or spleen, abnormal liver blood tests, or enlarged veins in the esophagus (seen on a camera test).
- Your baby does not have epilepsy, any neurological or bleeding disorder, diabetes, or certain types of biliary atresia.
- Your baby does not have severe health problems like cancer, organ failure (heart, lungs, liver, or kidneys), active infections, or serious mental health conditions.
- Your baby is not allergic to the medicines used for anesthesia.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if giving umbilical cord stem cells along with a standard surgery (Kasai procedure) helps infants with biliary atresia. It aims to see if this combination can improve outcomes for babies diagnosed early.
This study tests a medicine called GCSF (helps make white blood cells) in babies who have had Kasai surgery for biliary atresia. It aims to see if GCSF can improve liver function and overall outcomes.
This study follows babies under 6 months old who have early signs of liver disease (cholestasis) to better understand what causes it and how it progresses. Researchers will collect medical information over time to improve diagnosis and treatment.
This early-stage trial tests umbilical cord “mesenchymal” stem cells in people with liver scarring (cirrhosis) that is caused by hepatitis B. It may help improve liver function and related complications, but it is mainly designed to check safety and how well the treatment works.
This trial tests whether a type of stem cell therapy is safe for people with liver cirrhosis caused by alcohol, hepatitis B, or hepatitis C. It may help if your liver disease is controlled and you have moderate to severe cirrhosis.
This early-phase study tests whether stem cells (called mesenchymal stem cells) are safe and can help people with a sudden, severe liver failure. You may qualify if your liver is failing quickly and you are not eligible for a transplant.
Hear when a new Biliary Atresia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.